Absci is trading 9.83% up now at $8.83 after presenting encouraging interim ABS-201 Phase I/II results.
- No serious adverse events were reported among 32 volunteers.
- The drug showed an estimated half-life of at least 65 days.
- Results were presented at the Morgan Stanley Global Healthcare Conference on September 16, 2026; the broader market rally may have added support, with major indexes also higher on September 17.